Key facts
- Lumiris Spectral Solutions’s last known valuation is $20.3M (Oct 2024).
- It has raised $4.2M; the latest was Early Stage VC ($2.6M) in Aug 2025.
- Notable investors include Pelliga Family Office, Scranton Enterprises.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Lumiris Spectral Solutions
- ·The full record, as it builds
Funding rounds
No funding rounds for Lumiris Spectral Solutions are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lumiris Spectral Solutions
Developer of hyperspectral technology designed to help parents in vitro fertilization journey. The company's platform uses non-invasive technology that delivers detailed color-coded images for analyzing embryo metabolism, surpassing the standard black-and-white images of embryo morphology, enabling medical professionals with detailed color-coded images for analyzing embryo metabolism, surpassing the standard black-and-white images of embryo morphology.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2023
- Employees
- 7
- Website
- lumiris.tech/
- Ownership
- Privately Held (backing)
Lumiris Spectral Solutions doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lumiris Spectral Solutions shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lumiris Spectral Solutions in its N-PORT filings yet. We sweep new filings monthly.